Financial Comparison: Prothena Corporation PLC (PRTA) vs. Its Competitors
Prothena Corporation PLC (NASDAQ: PRTA) is one of 295 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Prothena Corporation PLC to similar companies based on the strength of its earnings, valuation, institutional ownership, risk, analyst recommendations, profitability and dividends.
This is a breakdown of recent recommendations for Prothena Corporation PLC and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Prothena Corporation PLC||0||0||12||0||3.00|
|Prothena Corporation PLC Competitors||765||3039||11202||227||2.71|
Prothena Corporation PLC presently has a consensus price target of $79.73, suggesting a potential upside of 36.43%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.90%. Given Prothena Corporation PLC’s peers higher possible upside, analysts plainly believe Prothena Corporation PLC has less favorable growth aspects than its peers.
Valuation and Earnings
This table compares Prothena Corporation PLC and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Prothena Corporation PLC||$27.53 million||-$135.60 million||-14.18|
|Prothena Corporation PLC Competitors||$260.16 million||$66.28 million||-6.43|
Prothena Corporation PLC’s peers have higher revenue and earnings than Prothena Corporation PLC. Prothena Corporation PLC is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Prothena Corporation PLC has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500. Comparatively, Prothena Corporation PLC’s peers have a beta of 6.66, suggesting that their average stock price is 566% more volatile than the S&P 500.
This table compares Prothena Corporation PLC and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Prothena Corporation PLC||-527.56%||-33.20%||-27.66%|
|Prothena Corporation PLC Competitors||-5,526.32%||-452.23%||-43.24%|
Insider and Institutional Ownership
50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 3.1% of Prothena Corporation PLC shares are owned by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Prothena Corporation PLC peers beat Prothena Corporation PLC on 7 of the 12 factors compared.
Prothena Corporation PLC Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company’s pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.